trial

Dyad Oxytocin Study (DOS)

NCTId NCT02302209
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 104 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2017-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
104 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2011-04
Primary completion
2017-10
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Josh D Woolley, MD/PhDPrincipal Investigator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
104
Phase
PHASE1
Primary Completion Date
2017-10
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Autism Spectrum Disorder
indication
Schizophrenia
indication
investigator
Josh D Woolley, MD/PhD
person